Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention

被引：29

作者：

Aponte, Maria M. Patarroyo ^{[1
]}

Francis, Gary S. ^{[1
]}

机构：

[1] Univ Minnesota, Med Ctr, Lillehei Heart Inst, Div Cardiovasc Med, Minneapolis, MN 55455 USA

来源：

CURRENT CARDIOLOGY REPORTS | 2012年 / 14卷 / 04期

关键词：

Atherosclerosis; Renin-angiotensin-aldosterone-system; Angiotensin-converting enzyme inhibitors; Angiotensin receptor blockers; Prevention; CORONARY-ARTERY-DISEASE; ENDOTHELIAL FUNCTION; ACE-INHIBITION; CARDIOVASCULAR EVENTS; ESSENTIAL-HYPERTENSION; COMBINATION THERAPY; TISSUE ANGIOTENSIN; RANDOMIZED-TRIAL; DOUBLE-BLIND; HIGH-RISK;

D O I：

10.1007/s11886-012-0275-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atherosclerosis is a highly complex biological process that has become the scourge of modern civilization. Endothelial dysfunction is the first step in the development of atherosclerosis. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the development of endothelial dysfunction and atherosclerosis. Several studies have shown that in vitro blockade of the RAAS is associated with improvement in markers of endothelial dysfunction and inflammation. Many clinical trials have demonstrated a clear benefit of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) manifested by a reduction of cardiovascular events. These findings suggest that ACEIs and ARBs can play an important role in prevention of atherosclerosis and in the delay of its progression. In this review we focus on the importance of RAAS blockade to prevent or delay progression of atherosclerosis and its impact on reduction of cardiovascular events.

引用

页码：433 / 442

页数：10

共 66 条

[1]

ABERG G, 1990, J CARDIOVASC PHARM, V15, pS65, DOI 10.1097/00005344-199000155-00010

[2] RETRACTED: Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease - A randomized trial (Retracted article) [J].

Ahimastos, AA ;

Lawler, A ;

Reid, CM ;

Blombery, PA ;

Kingwell, BA .

ANNALS OF INTERNAL MEDICINE, 2006, 144 (09) :660-664

[3] ACE inhibition and endothelial function:: Main findings of PERFECT, a sub-study of the EUROPA trial [J].

Bots, M. L. ;

Remme, W. J. ;

Luescher, T. F. ;

Fox, K. M. ;

Bertrand, M. ;

Ferrari, R. ;

Simoons, M. L. ;

Grobbee, D. E. .

CARDIOVASCULAR DRUGS AND THERAPY, 2007, 21 (04) :269-279

[4]

Braunwald E, 2004, NEW ENGL J MED, V351, P2058

[5] Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet [J].

Cashin-Hemphill, L ;

Holmvang, G ;

Chan, RC ;

Pitt, B ;

Dinsmore, RE ;

Lees, RS .

AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (01) :43-47

[6] ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT [J].

Ceconi, Claudio ;

Fox, Kim M. ;

Remme, William J. ;

Simoons, Marteen L. ;

Bertrand, Michael ;

Parrinello, Giovanni ;

Kluft, Cornelius ;

Blann, Andrew ;

Cokkinos, Dennis ;

Ferrari, Roberto .

CARDIOVASCULAR RESEARCH, 2007, 73 (01) :237-246

[7] Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients [J].

Ceriello, A ;

Assaloni, R ;

Da Ros, R ;

Maier, A ;

Piconi, L ;

Quagliaro, L ;

Esposito, K ;

Giugliano, D .

CIRCULATION, 2005, 111 (19) :2518-2524

[8] ANTIATHEROGENIC EFFECT OF CAPTOPRIL IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT [J].

CHOBANIAN, AV ;

HAUDENSCHILD, CC ;

NICKERSON, C ;

DRAGO, R .

HYPERTENSION, 1990, 15 (03) :327-331

[9] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[10] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].

Dahlöf, B ;

Sever, PS ;

Poulter, NR ;

Wedel, H ;

Beevers, DG ;

Caulfield, M ;

Collins, R ;

Kjeldsen, SE ;

Kristinsson, A ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Östergren, J .

LANCET, 2005, 366 (9489) :895-906

← 1 2 3 4 5 6 7 →